Skip to main content
Premium Trial:

Request an Annual Quote

Znomics Inks Drug-Discovery Collaboration with OHSU

NEW YORK (GenomeWeb News) — Zebrafish-screening firm Znomics said today that it is collaborating with Oregon Health & Science University to develop pre-clinical compounds to treat diseases such as rheumatoid arthritis, asthma, and inflammatory bowel syndrome.
The company said it will be collaborating with Thomas Scanlan, director of OHSU’s chemical biology program, on the project. Scanlan has been a member of Znomics' scientific advisory board since December 2007.
Under the terms of the agreement, Znomics will fund the program and will have the option to exclusively license the rights to the discoveries.
The company said that the collaboration meets its objective of establishing three de novo drug discovery programs this year, and that it plans to have three pre-clinical lead compounds in different disease areas in 2010.
In addition to the disease areas covered in the OHSU collaboration, the firm has a drug discovery program in obesity and a collaborative drug discovery program with the University of Utah that it signed earlier this year to develop compounds for the treatment of T-cell diseases, including leukemia, lymphoma, and autoimmune disorders.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.